Following a class action lawsuit that alleges some Apple Watch bands contain toxic "forever chemicals," also known as per- ...

California wildfires have already inflated costs for U.S. property insurance companies over the past 30 years, S&P said, driving up premiums, shaping underwriting practices and challenging regulatory ...

Allete Chief Financial Officer Steven Morris plans to step down after almost 25 years with the energy company. The Duluth, Minn., company said on Friday that Morris will retire mid-year as part of a ...

Washington, D.C. — At Department of Agriculture Secretary nominee Brooke Rollins’ Senate Confirmation hearing today, the ...

Frustrated by regulators ignoring their pleas for protection from a cancer-causing fumigant, farmworkers and their supporters ...

The order Trump signed sets up a crypto working group that is expected to propose a federal regulatory framework governing the issuance and operation of digital assets. It also calls for the group to ...

In a significant address at Davos, President Trump unveiled plans to position the US as a global frontrunner in AI and cryptocurrency. Highlighting major investments, he emphasized a strategy of ...

In 2025, compliance carbon allowance programs are poised for significant changes that could redefine the market's outlook ...

The details of Trump's plans to cut housing costs are yet to be announced. In the executive order, Trump ordered government agencies to deliver "emergency price relief" and take action to lower the ...

As he does regular weightlifting, Wickramasinghe, in his day job of parsing the markets, is projecting that the Straits Times Index (STI), already up 18% last year to around 3,800 points now, can be ...

In a sweeping policy shift, the Trump administration has repealed 78 executive orders from former President Joe Biden's administration, including crucial directives on AI development and safety ...

In this issue: clinical trial challenges and developments to keep an eye on in 2025, navigating the red tape around radiopharmaceutical trials, assessing the M&A potential this year in biopharma, and ...